← All trials
NCT05082259
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2021
- Primary completion
- Mar 16, 2026
- Completion date
- Mar 16, 2026
- First posted
- Oct 18, 2021
- Last posted
- Oct 27, 2021
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LondonLead sponsor
- MerckCollaborator
- Royal Marsden Hospital NHS TrustOverall official - principal investigator
- Cancer Research UKCollaborator
- Astex Pharmaceuticals, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.